![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Zhejiang Hongchang Electrical Technology
301008
5
Wuhan Lincontrol Automotive Electronics Co., Ltd.
688667
US Stock MarketDetailed Quotes
TARA Protara Therapeutics
- 3.580
- +0.120+3.47%
Close May 2 16:00 ET
- 3.610
- +0.030+0.84%
Post 20:01 ET
138.11MMarket Cap-1.65P/E (TTM)
3.700High3.431Low493.59KVolume3.460Open3.460Pre Close1.78MTurnover1.55%Turnover RatioLossP/E (Static)38.58MShares10.48052wk High0.83P/B114.27MFloat Cap1.59552wk Low--Dividend TTM31.92MShs Float800.000Historical High--Div YieldTTM7.77%Amplitude1.040Historical Low3.603Avg Price1Lot Size
Protara Therapeutics Stock Forum
Sign in to post a comment
$Amplify Energy (AMPY.US)$ 18.92%
$Colombier Acquisition Corp II (CLBR.US)$ 21.44%
$Genprex (GNPX.US)$ 30.98%
$Intelligent Group (INTJ.US)$ 17.19%
$Mainz Biomed (MYNZ.US)$ 25.88%
$INVO Fertility (IVF.US)$ (NAYA) 137.07%
$Protara Therapeutics (TARA.US)$ 16.08%
$WW International (WW.US)$ 59.48%
$Colombier Acquisition Corp II (CLBR.US)$ 21.44%
$Genprex (GNPX.US)$ 30.98%
$Intelligent Group (INTJ.US)$ 17.19%
$Mainz Biomed (MYNZ.US)$ 25.88%
$INVO Fertility (IVF.US)$ (NAYA) 137.07%
$Protara Therapeutics (TARA.US)$ 16.08%
$WW International (WW.US)$ 59.48%
10
4
1
$Protara Therapeutics (TARA.US)$ da phuck is this all about
$Protara Therapeutics (TARA.US)$ going up today???
1
$Protara Therapeutics (TARA.US)$
TARA-002's impressive efficacy in bladder cancer represents significant potential for Protara with durable responses in a difficult-to-treat indication.
These interim Phase 2 results represent a meaningful clinical milestone for Protara Therapeutics. The BCG-Unresponsive NMIBC patient population is particularly important from a regulatory and commercial perspective, as it represents a well-defined group with high unmet medical need. The...
TARA-002's impressive efficacy in bladder cancer represents significant potential for Protara with durable responses in a difficult-to-treat indication.
These interim Phase 2 results represent a meaningful clinical milestone for Protara Therapeutics. The BCG-Unresponsive NMIBC patient population is particularly important from a regulatory and commercial perspective, as it represents a well-defined group with high unmet medical need. The...
3
$Protara Therapeutics (TARA.US)$
TARA-002 shows exceptional 100% initial response and 67% 12-month durability in difficult-to-treat BCG-Unresponsive NMIBC, with excellent safety profile.
The interim results from the Phase 2 ADVANCED-2 trial demonstrate remarkably strong efficacy signals for TARA-002 in both patient populations studied. The 100% complete response rate at any time and 67% 12-month durability in BCG-Unresponsive patients is particularly impressive given the...
TARA-002 shows exceptional 100% initial response and 67% 12-month durability in difficult-to-treat BCG-Unresponsive NMIBC, with excellent safety profile.
The interim results from the Phase 2 ADVANCED-2 trial demonstrate remarkably strong efficacy signals for TARA-002 in both patient populations studied. The 100% complete response rate at any time and 67% 12-month durability in BCG-Unresponsive patients is particularly impressive given the...
1
$Protara Therapeutics (TARA.US)$
Breakthrough Clinical Data: New Bladder Cancer Drug Shows Perfect Response Rate in Hard-to-Treat Patients
Breakthrough Clinical Data: New Bladder Cancer Drug Shows Perfect Response Rate in Hard-to-Treat Patients
1
$Protara Therapeutics (TARA.US)$
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
Protara Therapeutics (TARA) announced positive interim results from its Phase 2 ADVANCED-2 trial of TARA-002 for Non-Muscle Invasive Bladder Cancer (NMIBC). The trial showed impressive efficacy in both patient cohorts:
In the BCG-Unresponsive cohort (5 patients):
100% complete response rate at any time...
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
Protara Therapeutics (TARA) announced positive interim results from its Phase 2 ADVANCED-2 trial of TARA-002 for Non-Muscle Invasive Bladder Cancer (NMIBC). The trial showed impressive efficacy in both patient cohorts:
In the BCG-Unresponsive cohort (5 patients):
100% complete response rate at any time...
2
3
No comment yet
Market Insights
Discussing
BRK cash at new high: What to expect from Buffett’s meeting?
🎙️Discussion 1. Buffett said he won't sell Japanese stocks for the next ten years. What's your take? 2. In the face of market changes, do y
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Adria87 :
Magic 1983 : what the fuck is goin on here
Magic 1983 : com on baby fly